Recorded fact · drug.label_indication
drug.label_indication for pembrolizumab|non-small-cell-lung-cancer
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 6d87b5eb resolves to.
The record
| Fact id | 6d87b5eb70b79fadfea33482 |
|---|---|
| Entity | drug: pembrolizumab|non-small-cell-lung-cancer |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20260710 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor ab
Shown with dashes as hyphens. SHA-256 of the exact stored quote: fe5530a114270db72ee05babcd094c1fd72bd88c6df8fb02b7fb2a8ba7376ff1.
The value
{
"ingredient": "Pembrolizumab",
"conditionId": "non-small-cell-lung-cancer",
"conditionName": "Non-Small Cell Lung Cancer",
"matchedAlias": "Non-Small Cell Lung Cancer",
"context": "indication",
"brand": "KEYTRUDA",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "9333c79b-d487-4538-a9f0-71b91a02b287",
"labelEffectiveTime": "20260710",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: b6f3e926621bb081e07ff29da88a6ebc73614d1c4a2753a5f178f74a8e9453d0.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.